MA-TAKEDA-PHARMACEUTICAL
26.1.2021 12:37:11 CET | Business Wire | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK ) (“Takeda”) has earned an industry-leading position within the 2021 Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas evaluated by the Index, including being ranked first in Governance of Access. Takeda also demonstrated strong performance in the areas of health system strengthening, compliance and R&D capacity building, according to the Index.
“This honor underscores Takeda’s commitment to prioritizing patient needs by ensuring access to our life-transforming treatments,” said Christophe Weber, Takeda president and chief executive officer. “As a purpose-driven company that puts the patient at the center of everything we do, we are committed to not just inventing medicines but making sure patients can access transformative therapies.”
The AtM Index is a rigorous, biennial research project combining data-collection, verification, scoring and analysis that compares 20 of the world’s largest pharmaceutical companies on their efforts to address access to medicines. Takeda was ranked sixth overall, and achieved ‘top 10’ positions within the three technical areas evaluated: Governance of Access, Research & Development and Product Delivery. This included top ranking in Governance of Access.
“Takeda is humbled by our recognition within the latest Access to Medicine Index ,” added Ricardo Marek, president of the Growth & Emerging Markets Business Unit of Takeda. “Our ranking further illustrates how Takeda’s values are being lived across the company, and how our ‘Access First’ approach across Takeda’s Growth & Emerging Markets Region is helping patients overcome access challenges in a more sustainable manner.”
Other notable highlights from Takeda’s achievements in the 2021 Index include:
- Recognition for its focus on ‘end-to-end’ patient access to treatment. In fact, Takeda was cited for its focus on affordable access to medicines throughout the drug development process – from early-stage clinical development through product launch and commercialization. Takeda also led the Index’s 20 companies in the category of assessing access strategies for medicines that must be administered by healthcare practitioners (HCP).
- The company led the industry for R&D capacity building.
- Takeda earned an industry-leading position in the area of health system strengthening. Takeda’s Blueprint for Innovative Healthcare Access , a local community care program in Kenya and Rwanda focused on non-communicable diseases (NCDs), was recognized as a scalable and inclusive business model aimed to meet the access needs of a population at the very base of the economic pyramid
Susanne Weissbaecker, Global Head of Access to Medicines, Takeda, commented: “Takeda’s continued leadership position in the 2021 Index is a testament to the impactful initiatives that we have put in place to help patients access our innovative and potentially life-saving medicines, while helping strengthen health systems in partnership with local governments, NGOs, and industry partners. Takeda has and hope to continue to play our part in helping patients overcome access challenges worldwide - despite the global pandemic.”
About Takeda’s Access to Medicines Initiatives
Focusing on countries with less developed or evolving healthcare systems, Takeda’s Access to Medicines strategy forms part of the company’s commitments to enhance people’s health worldwide. It is designed to help strengthen healthcare systems, and to tackle barriers that limit patient access to medicines. This includes partnering to implement affordability-based Patient Assistance Programs (PAPs) for Takeda’s innovative treatment portfolio - notably in the fields of rare and complex diseases - along with efforts that go beyond medicines in areas such as Research & Development (R&D), and health system strengthening via its flagship Blueprint for Innovative Healthcare Access
program in Kenya and Rwanda.
About the Access to Medicine Index
The Access to Medicine Index is published every two years by the Access to Medicine Foundation
, an independent, not-for-profit organization and is funded by the Bill & Melinda Gates Foundation, plus the UK and Dutch governments. The 2021 Index tracks company action to rank 20 of the world’s largest pharmaceutical companies. It measures companies’ actions to improve access to medicine across 106 low- and middle-income countries and in relation to 82 high-burden diseases, conditions and pathogens. The analytical framework for 2021 has a new, focused structure, with 33 indicators grouped into three Technical Areas: Governance of Access; Research & Development; and Product Delivery.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK
) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in healthcare in approximately 80 countries. For more information, visit https://www.takeda.com
.
Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005569/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press release
Canada becomes the 25th Allied nation to back the NATO Innovation Fund, gaining access to €1.1 billion in mission-aligned capital and a co-investor network spanning the Alliance Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the amb
Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press release
Independent evaluation of Persona's Android SDK confirms defenses against deepfakes and other injected media at the top level of the first standard Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release
Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
